14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $227.75 $262.51 Friday, 3rd May 2024 UTHR stock ended at $262.40. This is 1.65% more than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 2.57% from a day low at $255.93 to a day high of $262.51.
90 days $208.62 $262.51
52 weeks $204.44 $262.51

Historical United Therapeutics Corporation prices

Date Open High Low Close Volume
Jun 09, 2023 $226.12 $229.32 $224.64 $228.49 269 164
Jun 08, 2023 $221.48 $227.25 $221.37 $226.50 363 962
Jun 07, 2023 $220.25 $222.30 $219.00 $220.66 272 780
Jun 06, 2023 $220.00 $220.88 $217.63 $220.25 310 559
Jun 05, 2023 $216.15 $219.87 $215.29 $218.88 275 476
Jun 02, 2023 $214.52 $217.65 $213.36 $217.22 384 352
Jun 01, 2023 $210.40 $214.54 $207.00 $213.48 415 035
May 31, 2023 $205.93 $211.25 $205.93 $209.74 1 067 096
May 30, 2023 $206.03 $208.20 $204.44 $205.19 294 308
May 26, 2023 $207.76 $213.93 $207.20 $207.32 350 972
May 25, 2023 $212.15 $213.82 $209.94 $212.14 478 708
May 24, 2023 $216.75 $217.71 $213.99 $214.09 199 980
May 23, 2023 $218.76 $219.60 $216.11 $216.19 262 424
May 22, 2023 $220.37 $221.86 $216.92 $218.59 340 402
May 19, 2023 $218.02 $220.28 $217.45 $219.56 305 682
May 18, 2023 $215.82 $216.82 $213.59 $216.79 285 463
May 17, 2023 $211.67 $216.65 $209.36 $216.19 414 543
May 16, 2023 $212.80 $213.49 $210.21 $212.05 199 250
May 15, 2023 $214.19 $215.38 $212.80 $214.40 268 240
May 12, 2023 $214.34 $214.73 $212.55 $214.02 327 116
May 11, 2023 $212.47 $213.66 $209.96 $213.48 200 374
May 10, 2023 $209.84 $212.74 $208.23 $212.24 310 082
May 09, 2023 $209.78 $211.15 $208.63 $209.60 376 624
May 08, 2023 $214.29 $216.11 $209.83 $210.46 457 275
May 05, 2023 $217.48 $217.79 $213.23 $214.12 913 086
Click to get the best stock tips daily for free!

About United Therapeutics Corporation

United Therapeutics United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin a... UTHR Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT